Levodopa–Entacapone–Carbidopa Intestinal Gel in advanced Parkinson’s disease: clinical positioning, candidate profiling, and implementation roadmap
Year: 2026
Type: article
Abstract: Device-aided therapies (DATs) for Parkinson’s disease (PD) with motor complications encompass deep brain stimulation (DBS), intrajejunal and subcutaneous infusions. Levodopa-carbidopa-entacapone intestinal gel (LECIG) infusion is the most recent strategy to be included in the intrajejunal class. By adding peripheral catechol-O-methyltransferase (COMT) inhibition, LECIG increases levodopa bioavailability, enabling a comparable dopaminergic effect at a reduced levodopa dose and infusion volume. Drawing on the discussion of a national advisory board of Italian movement disorder specialists, this perspective addresses the positioning of LECIG in PD patients with motor fluctuations. LECIG broadens the intrajejunal infusion landscape with a smaller device and potential metabolic advantages related to reduced 3-O-methyldopa generation. Two candidate scenarios predominate: the patient requiring a first infusional DAT after failure of optimized oral therapy who is ineligible for or declines DBS, and the patient already on a DAT with residual or worsening/re-emergent fluctuations. Favorable selection features include a levodopa-responsive, motor-fluctuation-predominant phenotype, documented COMT-inhibitor tolerance, absence of overt dementia with adequate caregiver support, a rationale for levodopa dose sparing (e.g., peripheral neuropathy risk), and concomitant dysphagia that features an additional niche benefitting of intestinal therapies. Cautionary or unfavorable features include levodopa-resistant axial disability, severe cognitive impairment, absence of caregiver support, COMT-inhibitor intolerance, and active neuropsychiatric symptoms, other than gastrointestinal contraindication for receiving gastrojejunostomy. Implementation barriers include the need for structured gastroenterology collaboration, and a potential cost-per-quality-adjusted-life-year higher than comparator DATs. Precise, multidimensional patient selection, together with a prescribing roadmap, with prospective registries, and structured multidisciplinary agenda, could be the cornerstone of optimizing outcomes.
Source: Frontiers in Neurology
Institutions: Università Campus Bio-Medico, Campus Bio Medico University Hospital, University of Verona, Institut polytechnique de Grenoble, Centre National de la Recherche Scientifique, Laboratoire d'Informatique de Grenoble, Istituto Neurologico Mediterraneo, Sapienza University of Rome, Azienda Sanitaria Unità Locale di Reggio Emilia, Azienda USL di Pescara, Azienda Ospedaliero-Universitaria Cagliari, University of Pavia, King's College London, Fondazione IRCCS Istituto Neurologico Carlo Besta, University of Campania "Luigi Vanvitelli"
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7225862360
